We examined the dose of radiation received during diagnosis of lung cancer as this may add to the risk of a second primary cancer. Patients undergoing surgery (n=40) or (chemo)radiotherapy (n=40) received comparable doses (28.6 and 25.8 mSv, respectively), significantly higher than that for supportive care (n=40; 15.1 mSv). The effective dose of radiation received was higher for early stage disease than for those with metastatic disease. The mean lifetime attributable risk of malignancy for those receiving treatment with curative intent in our cohort was 0.059%, and lung-specific risk 0.019%.
- Lung Cancer
- Imaging/CT MRI etc
Statistics from Altmetric.com
Contributors The original project was conceived by ERC. All authors developed the methodology. RA and KT collected data which were analysed by RA, RCR and ERC. RCR produced the first draft of the manuscript which was reviewed and approved by all.
Funding RCR is part-funded by the Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Centre.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.